Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

PURPOSE: The question whether the new cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs aimed at restoring CFTR protein function might improve glucose metabolism is gaining attention, but data on the effect of lumacaftor/ivacaftor treatment (LUMA/IVA) on glucose tolerance ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, C., Foppiani, A., Bisogno, A., Gambazza, S., Daccò, V., Nazzari, E., Leone, A., Giana, A., Mari, A., Battezzati, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421269/
https://www.ncbi.nlm.nih.gov/pubmed/33586024
http://dx.doi.org/10.1007/s40618-021-01525-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421269/
https://www.ncbi.nlm.nih.gov/pubmed/33586024
http://dx.doi.org/10.1007/s40618-021-01525-4

Ejemplares similares